MorphoSys Achieves Fourth Therapeutic Milestone in Centocor Collaboration
News Feb 28, 2006
In meeting the milestone, MorphoSys developed several highly optimized fully human IgG antibodies using its proprietary HuCAL GOLD® antibody library against a Centocor target involved in inflammatory and auto-immune diseases.
As part of the collaboration milestone, MorphoSys applied its proprietary HuCAL GOLD® antibody library in order to generate antibodies which passed pre-defined criteria. Achievement of the milestone triggered a payment from Centocor to MorphoSys.
The cooperation between MorphoSys and Centocor, initiated in December 2000, is aimed at the development of human therapeutic antibodies in a range of indications.
In December 2004 the collaboration was extended by another three years. Within the scope of the collaboration, Centocor has access to HuCAL GOLD® for the development of therapeutic antibodies as well as for research purposes.
Additionally, Centocor uses AutoCAL™, the MorphoSys-developed system for automated screening of the HuCAL® antibody library.
In September 2005, both companies launched an antibody program to develop a therapeutic antibody against a Centocor target molecule involved in immune-mediated and inflammatory diseases.
"Our successful collaboration with Centocor continues to deliver progress towards new therapeutic antibodies, as evidenced by this fourth successful therapeutic milestone," commented Dr. Simon Moroney, Chief Executive Officer of MorphoSys AG.
Unlike most cells in the rest of our body, the DNA (the genome) in each of our brain cells varies from cell to cell, caused by somatic changes. But much remains unknown, including when these changes arise, their size and locations, and whether they are random or regulated. Now, researchers have developed new techniques allowing the detection of CNVs smaller than one million base pairs.